Indolent @entity1893 ( @entity1893 ) are essentially incurable with current treatments. Rituximab is a specific anti- @entity12950 chimeric monoclonal antibody against the @entity12950 , which is stably expressed on most B-cells (from the pre-B-cell stage). Compared with chemotherapy, rituximab has an excellent tolerability profile, making it a good therapeutic option for @entity1 with indolent @entity1893 . In the pivotal study for rituximab, @entity1 with relapsed or refractory indolent or @entity706 ( @entity706 ) had an overall response rate of 50%. There is evidence that first-line rituximab therapy may be associated with better response rates; in previously untreated @entity706 with a @entity5 burden, rituximab monotherapy has produced an overall response rate of 73%. Attempts to improve response rates to rituximab by increasing the dose or frequency of dosing showed that the addition of four extra infusions of rituximab (in addition to the standard treatment schedule) resulted in an overall response rate of 76% in @entity1 with @entity706 . Augmenting rituximab with cytokines is also an option for increasing response rates in @entity1 with indolent @entity1893 . In a trial by the @entity706 Study Group in @entity1 with previously untreated or first-relapse indolent @entity1893 , who had stable disease or a partial response after four doses of rituximab, 48% of the @entity1 treated with rituximab plus @entity4020 achieved a complete response. A further option is to combine rituximab with chemotherapy. Interim analyses from the East German Study Group have shown that rituximab plus @entity2664 , @entity5805 and @entity617 (MCP) resulted in overall response rates of 89% in @entity1 with untreated @entity706 . Rituximab is therefore an excellent treatment option both as first-line and as salvage therapy for @entity1 with indolent @entity1893 .

Rituximab therapy for indolent XXXX .

@entity1 :: ('9606', 'Species') :: ['patients'] @entity4020 :: ('3440', 'Gene') :: ['interferon-alpha2a'] @entity706 :: ('MESH:D008223', 'Disease') :: ['FL', 'Nordic Lymphoma', 'indolent lymphoma', 'follicular lymphoma'] @entity617 :: ('MESH:D011239', 'Chemical') :: ['prednisolone'] @entity5 :: ('MESH:D009369', 'Disease') :: ['low tumor'] @entity2664 :: ('MESH:D008942', 'Chemical') :: ['mitoxantrone'] @entity5805 :: ('MESH:D002699', 'Chemical') :: ['chlorambucil'] @entity1893 :: ('MESH:D008228', 'Disease') :: ['NHL', "non-Hodgkin's lymphomas", 'NHLs'] @entity12950 :: ('931', 'Gene') :: ['CD20', 'CD20 antigen']
@entity1893 :: (MESH:D008228,Disease) :: ['non-Hodgkin's lymphoma']
